Quantitative ultrasound image analysis of axillary lymph nodes to differentiate malignancy from reactive benign changes due to COVID-19 vaccination

Coronado-Gutiérrez, David; Ganau, Sergi; Bargalló, Xavier; Úbeda, B.; Porta, Marta; Sanfeliu, Esther; Burgos-Artizzu, Xavier P.

doi:10.1016/j.ejrad.2022.110438

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can lead to the proliferation of cells mimicking a neoplastic process. 10,11 The same process was present in the biopsy seen in our patient. The ideal approach is to correlate with radiology, clinical history, and patient follow up.…”

Section: Discussionsupporting

confidence: 79%

Langerhans Cell Hyperplasia Mimicking Langerhans Cell Histiocytosis: A Rare Complication of COVID-19 Vaccination

Qureshi,

Al Khabori,

Al Haddabi

et al. 2023

Int J Surg Pathol

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) is a rare disorder characterized by the abnormal proliferation of Langerhans cells, a type of immune cell that is normally present in the skin and various other tissues. LCH can affect people of any age but is most commonly diagnosed in children. We report a case of a patient with LCH who developed ipsilateral axillary lymphadenopathology post-COVID-19 vaccination. Lymph node biopsy showed diffuse Langerhans cell hyperplasia which mimicked LCH. Clinically and radiologically, it looked to be a reactive lymph node. The patient was kept on follow up only and after 1 year of follow up the size of lymph nodes regressed confirming to be reactive in nature rather than neoplastic. To the best of our knowledge, this is the second case of Langerhans cell hyperplasia post-COVID-19 vaccination being reported in the literature.

show abstract

Section: Discussionsupporting

confidence: 79%

Langerhans Cell Hyperplasia Mimicking Langerhans Cell Histiocytosis: A Rare Complication of COVID-19 Vaccination

Qureshi,

Al Khabori,

Al Haddabi

et al. 2023

Int J Surg Pathol

View full text Add to dashboard Cite

show abstract

“…In our population, the rate of lymphadenopathy rose to 1.4%. Many studies highlighted the frequency of axillary nodes after covid vaccination, and the challenges caused in the oncology imaging ( 27 – 29 ). Even though lymph nodes could only be linked to cancer history, a prospective study of 232 cancer patients found an increase in regional nodes after COVID vaccination ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report

Lamtai¹,

Boutayeb²,

Mrabti³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe SARS-CoV-2 pandemic has slowed down cancer prevention and treatment strategies; consequently, cancer patients are prioritized to get the COVID-19 vaccines. Being constantly threatened by a new outbreak, the dive within the immunogenicity response is of great value; nonetheless, evaluating the side effects of these vaccines on fragile patients will assure their adherence to the vaccination protocol.ObjectivesThis study sets out to investigate the adverse events reported about the vaccine according to its doses and types, and to compare the prevalence and severity of toxicities across two subgroups of cancer patients, those who received the injection during active therapy cycles, and those who have not started the therapy yet at vaccination time, moreover, this paper examines the will and commitment of this population to the vaccination schemes.MethodsThis is an observational, retrospective, cohort study, in which we conducted a semi-constructed interview with 415 random solid cancer patients treated at the National Institute of Oncology in Morocco. The assessment of adverse events was carried out with a standardized scale.ResultsEleven months after the launch of the campaign, 75.2% of patients received at least one dose of the vaccine. Altogether, the analysis demonstrates a significant difference between the adverse effects reported post the second dose compared to the first one (p=0.004; odds ratio=2 [95% CI: 1.23 - 3.31]). Besides, the results indicate an increase in the rank of the severity of systemic events (p<0.001, r=0.28) after the second dose, but not for the local events (p=0.92, r=0.005). In the adjusted subgroup analysis, no effect was detected linking active therapy with the occurrence of toxicity (p=0.51, v=0.04) as well as with the level of severity reported after both; the first and second dose. Due to the fear of interactions with the therapy, we noticed a significant trend to delay the booster dose among the participants who completed the initial vaccine protocol.ConclusionA considerable body of evidence exists to persuade cancer patients to take the Coronavirus vaccines, and to also follow their vaccination schemes under the supervision of their treating physicians.

show abstract

“…(c) Among neuro-oncological cases, it is noteworthy that no glioblastoma was surgically removed. Surgery did not appear adequate in any of the 16 In this second period where the availability of operating theaters doubled from 1 to 2 a week in each hospital, the global neurosurgical activity regarding the case mix remained very similar to the previous activity with non-significant differences (Table 3); the only exception was regarding functional procedures (deep brain stimulation (DBS), epilepsy and pain surgery, and spastic rigidity managed by intrathecal baclofen) that were further systematically postponed, causing a heavy medical and ethical issue that will be discussed in more detail in the discussion section. From March 2020 to March 2022, 90 patients affected by Parkinson's disease, 53 affected by resistant and medically intractable epilepsy, 137 affected by resistant and intractable pain, and 22 affected by spastic rigidity were not managed, presenting a catastrophic evolution with most of them having a poor and not completely reversible functional outcome.…”

Section: Relevant Pathologies Impactedmentioning

confidence: 96%

“…In critical situations, neurosurgeons encountered the difficulties of allocating scarce healthcare resources, leading to increased mortality or significantly less favorable outcomes, particularly in oncology patients [ 13 , 14 , 15 ]. Many countries and international scientific societies rapidly developed and approved new recommendations, best practices, and checklists for immediate implementation [ 16 , 17 , 18 , 19 , 20 , 21 ]. The northeastern part of France witnessed a notably high number of recorded cases, emerging as one of the pandemic’s epicenters in the country and throughout continental Europe.…”

Section: Introductionmentioning

confidence: 99%

Effects of the COVID-19 Pandemic on Everyday Neurosurgical Practice in Alsace, France: Lessons Learned, Current Perspectives, and Future Challenges—Preliminary Results of a Longitudinal Multicentric Study Registry

Dannhoff,

Mallereau,

Ganau

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: The global outbreak caused by the SARS-CoV-2 pandemic disrupted healthcare worldwide, impacting the organization of intensive care units and surgical care units. This study aimed to document the daily neurosurgical activity in Alsace, France, one of the European epicenters of the pandemic, and provide evidence of the adaptive strategies deployed during such a critical time for healthcare services. Materials and Methods: The multicentric longitudinal study was based on a prospective cohort of patients requiring neurosurgical care in the Neurosurgical Departments of Alsace, France, between March 2020 and March 2022. Surgical activity was compared with pre-pandemic performances through data obtained from electronic patient records. Results: A total of 3842 patients benefited from care in a neurosurgical unit during the period of interest; 2352 of them underwent surgeries with a wide range of pathologies treated. Surgeries were initially limited to neurosurgical emergencies only, then urgent cases were slowly reinstated; however, a significant drop in surgical volume and case mix was noticed during lockdown (March–May 2020). The crisis continued to impact surgical activity until March 2022; functional procedures were postponed, though some spine surgeries could progressively be performed starting in October 2021. Various social factors, such as increased alcohol consumption during the pandemic, influenced the severity of traumatic pathologies. The progressive return to the usual profile of surgical activity was characterized by a rebound of oncological interventions. Deferrable procedures for elective spinal and functional pathologies were the most affected, with unexpected medical and social impacts. Conclusions: The task shifting and task sharing approaches implemented during the first wave of the pandemic supported the reorganization of neurosurgical care in its aftermath and enabled the safe and timely execution of a broad spectrum of surgeries. Despite the substantial disruption to routine practices, marked by a significant reduction in elective surgical volumes, comprehensive records demonstrate the successful management of the full range of neurosurgical pathologies. This underscores the efficacy of adaptive strategies in navigating the challenges imposed by the largest healthcare crisis in recent history. Those lessons will continue to provide valuable insights and guidance for health and care managers to prepare for future unpredictable scenarios.

show abstract

Quantitative ultrasound image analysis of axillary lymph nodes to differentiate malignancy from reactive benign changes due to COVID-19 vaccination

Cited by 4 publications

References 18 publications

Langerhans Cell Hyperplasia Mimicking Langerhans Cell Histiocytosis: A Rare Complication of COVID-19 Vaccination

Langerhans Cell Hyperplasia Mimicking Langerhans Cell Histiocytosis: A Rare Complication of COVID-19 Vaccination

Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report

Effects of the COVID-19 Pandemic on Everyday Neurosurgical Practice in Alsace, France: Lessons Learned, Current Perspectives, and Future Challenges—Preliminary Results of a Longitudinal Multicentric Study Registry

Contact Info

Product

Resources

About